Summary This clinical study is looking at a new drug called CCT245737 which looks promising in laboratory studies when given with other cancer medicines (known as chemotherapy). We now wish to find out if it will be useful in treating patients with cancer when given with chemotherapy. The chemotherapy used in this study will either be gemcitabine plus cisplatin or gemcitabine alone. Both of these chemotherapies are currently used as standard treatments for cancer. CCT245737 is a type of drug called a kinase inhibitor. It blocks a chemical messenger (enzyme) called checkpoint kinase 1 (CHK-1) which is part of the signaling process within cells which can make cells produce chemicals that trigger and control cell growth and cell death. Chemotherapy agents are used to try to kill cancer cells however sometimes cancer cells can repair themselves using these signaling processes and continue to grow. CCT245737 may help chemotherapy to work better by preventing cancer cells from repairing themselves, when they have been damaged by chemotherapy, so that more cancer cells could be killed. There are 2 stages to this study: 1)Patients in Stage 1 will be given CCT245737 in addition to receiving treatment with gemcitabine and cisplatin. 2)Patients in Stage 2 will be given CCT245737 in addition to receiving treatment with gemcitabine only. Each stage of the study will be split into two parts: Part one will be a ‘dose escalation’ phase where groups of patients will receive increasing doses of the CCT245737 to find the best dose to treat patients with. Part two will be an ‘expansion phase’ where a larger group of patients will be treated at the highest dose level of CCT245737 considered to be safe from part one to find out more about how the drug is working.
A useful opportunity (courtesy of Investegate.co.uk), to reflect upon the journey travelled by the Company, from it's inception to the present date and which in addition, also highlights the considerable number of associated commercial opportunities stemming from our various compound developments:
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.